Former subsidiary of the Roche Group operating the largest production site for sterile ampoules in Europe, Cenexi became an independent company in 2008. The company acquired two new production sites in Osny in France and in Braine l’Alleud in Belgium, respectively specialized in solid forms of hormonal and anti-allergy products and injectable oncologic products. Cenexi has also developed an offering of complementary services, including formulation, analytical development, product portfolio transfer management and regulatory support. These developments have allowed the company to enhance its client base, which today includes over 80 clients, and which mainly consists of international pharmaceutical groups, both generalist and specialist entities. Leveraging its solid industrial know-how and its operational excellence, all of Cenexi’s sites are registered with major world health authorities (FDA, Japan, China…), which allows the group to distribute its products in over 150 countries.
Location: Metropolitan France
Employees: 1001-5000
Founded date: 2004
Investors 2
| Date | Name | Website |
| - | Cathay Cap... | cathaycapi... |
| - | Invest.BW | investbw.b... |
Mentions in press and media 3
| Date | Title | Description |
| 16.05.2024 | Fosun attends "Choose France" Summit for a third time | HONG KONG, May 16, 2024 /PRNewswire/ -- On 13 May 2024, Guo Guangchang, Chairman of Fosun International, attended the Choose France Summit hosted by the French government in Paris. During the summit, Guo Guangchang engaged in discussions wi... |
| 29.11.2022 | Gland Pharma to acquire Cenexi group at an equity value of €120 m | Gland Pharma, through its arm Gland Pharma International PTE. Ltd, Singapore, entered into a put option agreement to acquire France-based Cenexi Group for an equity value not exceeding €120 million (enterprise value of €230 million). “This ... |
| 30.06.2021 | OSE Immunotherapeutics Announces Manufacturing Agreement with Cenexi for Clinical Batches of CoVepiT, OSE's Multi-Target Second-Generation COVID-19 Vaccine | NANTES, France and FONTENAY-SOUS-BOIS, France, June 30, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) and Cenexi, a French contract development and manufacturing organization (CDMO), today announced the si... |